Recently, Grand Shuyang's new pre-filled syringe formulation of Human Tetanus Immunoglobulin has received the relevant marketing approvals, marking a significant step forward for the Company in upgrading the dosage forms of human immunoglobulin products, enhancing clinical convenience, and refining quality management.

From product R&D to process validation, and from quality control to regulatory approval, Grand Shuyang remains committed to prioritizing clinical needs and upholding quality and safety as its bottom line. The Company continuously works to upgrade its blood product offerings and service capabilities, providing medical institutions with more standardized, convenient, and reliable product options.

Focusing on Clinical Needs   Making emergency use more convenient and product preparation more efficient

Tetanus prevention and treatment are commonly used in various emergency trauma-related clinical settings, where clinical medications must meet high standards for product availability, ease of use, and adherence to proper protocols.Pre-filled syringes contain drug solutions pre-loaded into syringes, offering the advantages of clear dosage indicators, convenient access, and simplified administration processes.This newly marketed pre-filled syringe of human tetanus immunoglobulin significantly streamlines pre-dosing clinical procedures, eliminating traditional processes including medication dispensing, solution aspiration, and drug transfer. This not only improves the efficiency and convenience of clinical use in medical institutions but also prevents potential contamination risks of drug solutions from multi-step operations.Each upgrade cycle of pharmaceuticals focuses on addressing clinical requirements—enhancing product identifiability, accessibility, and controllability for patient care.

Towards Innovation  To be a trustworthy blood products manufacturer  

Every product enhancement responds to clinical demands;

Every process optimization upholds quality responsibility;

Every new product introduction demonstrates sustained corporate innovation capabilities.

Grand Shuyang will continue to uphold a professional, rigorous, and responsible approach, deepen expertise in the blood products field, and drive continuous product innovation and quality improvement. With a more comprehensive product portfolio and service system, the Company supports the high-quality development of the healthcare sector.

Note: This information is provided solely to introduce the Company's brand and product marketing and does not constitute medical advice. For specific indications, dosage and administration, contraindications, adverse reactions, and precautions, please refer to the approved package insert and follow the guidance of healthcare professionals.